UroToday1d
SES AUA 2025: Identifying Key Mutations Linked to Metastasis in Clear Cell Renal Cell Carcinoma: A GENIE Database Analysis
(UroToday.com) The 2025 SESAUA annual meeting featured a kidney cancer session and a presentation by Reynier Rodriguez Rosales discussing a GENIE database analysis identifying key mutations linked to ...
UroToday1d
SES AUA 2025: PSA Dynamics from the Phase 3 EMBARK Trial: A Post Hoc Analysis
SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Paul Sieber discussing a post hoc analysis ...
UroToday1d
SES AUA 2025: Validation of PAM50 for Predicting Progression in Active Surveillance: Results from the Miami MAST Prospective Clinical Trial
SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Jamie Thomas discussing results from the MAST trial assessing the validation of PAM50 for predicting progression in ...
UroToday2d
SES AUA 2025: Evaluation of Systemic Therapy and Surgical Consolidation in Patients with Node Positive UTUC
SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Joon Kyung Kim discussing an evaluation of ...
UroToday2d
SES AUA 2025: Germline Testing for Renal Cancers – How Age and Tumor Characteristics Affect Pathogenic Variants
SESAUA annual meeting featured a kidney cancer session and a presentation by Dr. Robert Smith discussing how age and tumor ...
UroToday3d
Bladder Cancer Videos
Treatment Options for Bladder Cancer: Bringing Life to Years of Sparse Options - Guru Sonpavde ...
UroToday3d
The Optimal Treatment for Gleason Score 9-10 Prostate Cancer
Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
UroToday3d
SES AUA 2025: ENVISION: Primary Chemoablation of Recurrent Low-Grade Intermediate Risk NMIBC with UGN-102: A Single-Arm, Open-Label, Phase 3 Trial
Low grade non-muscle invasive bladder cancer (Ta) confirmed by cystoscopy and cold cup biopsy of the visualized tumor at screening or within 8 weeks before screening Negative voiding cytology for high ...
UroToday3d
SES AUA 2025: Oncologic Efficacy of Reduced versus Standard-Dose BCG for NMIBC
SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Meredith Bernhard discussing the oncologic efficacy of reduced versus standard-dose BCG for non muscle invasive ...
UroToday3d
APCCC Diagnostics 2025: False Positive PSMA PET: What to Know?
(UroToday.com) The Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics 2025, held in Lugano, Switzerland, on February 27 th and 28 th, was host to a session addressing the contemporary ...